3 transcripts
REGN
Earnings call transcript
NASDAQ
2024 Q2
1 Aug 24
is needed to be remediated, but because of the nature of the observations, a reinspection is necessary, we believe, based on what we've been told
REGN
Earnings call transcript
NASDAQ
2024 Q1
2 May 24
and naturally, people have then started talking about T cell engagers. This seems like a natural place where Regeneron could leverage its bispecific
REGN
Earnings call transcript
NASDAQ
2023 Q2
3 Aug 23
-1 I guess the natural observation here is Regeneron doesn't currently have a program in development. Is there any interest in acquiring one
- Prev
- 1
- Next